

Kidney Cancer GCOM 11 (day 2) minutes

Kidney Cancer update – committee meeting 11 (day 2) minutes

Date: 08/05/2025

Location: Virtual

Minutes: Final

Committee members present:		
Baljit Singh	Chair	Present for items 1-7
Axel Bex	Urological Surgeon	Present for items partway through item 5-7
Lisa Browning	Histopathologist	Present for items 1-4
Amy Clifford	Clinical Oncologist (SABR)	Present for items 1-7
John Connolly	Lay Member	Present for items 1-7
David Cullen	Urology Cancer Nurse	Present for items 1-7
Stuart Evans	Oncology Pharmacist	Present for items 1-7
Geraldine Fox	Lay Member	Present for items 1-7
Fayiza Habeeb	Lead Nurse Practitioner	Present for items 1-7
David Mole	Nephrologist (co-opted member)	Present for items 5-7
Ana Semedo	Vice Chair, Oncology Cancer Nurse	Present for items 1-7
Sandeep Singh Randhawa	General Practitioner	Present for items 1-7
Grant Stewart	Topic Adviser	Present for items 1-4, 6-7
Sam Withey	Diagnostic Radiologist	Present for items 1-7
Rose Woodward	Lay member	Present for items 1-7

In attendance NICE:		
Marie Harrisingh	Topic Lead	Present for items 1-7
Sarah Boyce	Senior Technical Analyst	Present for items 1-7
Danielle Conroy	Project Manager	Present for items 1-7
Lindsay Claxton	Health Economics Adviser	Present for items 1-7
Benjamin Gregory	Business Analyst, Resource Impact	Present for items 4-7
Lina Manounah	Technical Analyst	Present for items 6-7
Agnesa Mehmeti	Technical Analyst	Present for items 1-7
Hannah Tebbs	Senior Health Economist	Present for items 1-7
Ellie Zachariades	Senior Guidance Content	Present for items 1-7

	Designer	
Yuanyuan Zhang	Senior Health Economist	Present for items 1-7

In attendance external:

Elena Pizzo	Professorial Research Fellow, Health Economist, University College London - Expert Witness	Present for item 3
-------------	--	--------------------

Apologies:

Janet Brown	Medical Oncologist, committee member
Victoria Carter	Implementation Support Manager, NICE
Amarnath Challapalli	Clinical Oncologist (General), committee member
Olivia Crane	Senior Technical Analyst, NICE
Fayiza Habeeb	Lead Nurse Practitioner, committee member
Vishal Patil	Anaesthetist (co-opted member), committee member
Ankit Rao	Medical Oncologist, committee member
Maxine Tran	Urological Surgeon, committee member
Tze Min Wah	Interventional Radiologist, committee member
James Whitworth	Clinical Geneticist (co-opted member), committee member

1. Welcome, Introductions and DOIs

The Chair, Baljit Singh (BS) welcomed the committee members and NICE attendees to day 2 of the 11th committee meeting for the NICE Kidney Cancer guideline.

BS informed attendees that apologies had been received as noted above. BS asked all committee members to verbally declare any new interests.

No new interests were declared but BS reminded the group of the following recorded interest which are relevant to the day's discussion:

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
Professor Axel Bex	Consultant Urologist and Clinical Lead Specialist	Ranieri, V., Warren, H., Florez, I., Neves, J.B., Walkden, M., Bernstein, D.E., Santiapillai, J., Williams, N., Wildgoose, W.H.,	Specific, direct non-financial professional	Declare and partial exclusion. Participate in discussion but

Kidney Cancer GCOM 11 (day 2) minutes

	Centre for Kidney Cancer, Royal Free London NHS Foundation Trust, Specialist Centre for Kidney Cancer	Patki, P., Stewart, G.D., Kinsella, N., Pizzo, E., Barod, R., Bex, A., Mumtaz, F., El-Sheikh, S., Gurusamy, K. and Tran, M.G.B. (2024), Identifying the facilitators and barriers to implementation of renal tumour biopsy in the diagnostic pathway for small renal masses. BJU Int, 134: 796-804. https://doi.org/10.1111/bju.16470	and personal	withdraw from drafting recommendations about information to be provided about biopsy.
Professor Grant Stewart	Professor of Surgical Oncology, University of Cambridge, Honorary Consultant in Urological Surgery, Cambridge University Hospitals NHS Foundation Trust	Harrison, H., Stewart, G.D. and Usher-Smith, J.A. (2023), Patient experience of follow-up after surgery for kidney cancer: a focus group study. BJU Int, 132: 47-55. https://doi.org/10.1111/bju.15982	Specific, direct non-financial professional and personal	Declare and partial exclusion. Participate in discussion but withdraw from drafting recommendations about information needs.
Professor Grant Stewart	Professor of Surgical Oncology, University of Cambridge, Honorary Consultant in Urological Surgery, Cambridge University Hospitals NHS Foundation Trust	Ranieri, V., Warren, H., Florez, I., Neves, J.B., Walkden, M., Bernstein, D.E., Santiapillai, J., Williams, N., Wildgoose, W.H., Patki, P., Stewart, G.D., Kinsella, N., Pizzo, E., Barod, R., Bex, A., Mumtaz, F., El-Sheikh, S., Gurusamy, K. and Tran, M.G.B. (2024), Identifying the facilitators and barriers to implementation of renal tumour biopsy in the diagnostic pathway for small renal masses. BJU Int, 134: 796-804. https://doi.org/10.1111/bju.16470	Specific, direct non-financial professional and personal	Declare and partial exclusion. Participate in discussion but withdraw from drafting recommendations about information needs.

Grant Stewart (GS) was an author on 2 papers included in an evidence review (RQ1 on information needs) being discussed. It was agreed that the member would need to step out whilst recommendations were being made for this topic because his studies could contribute to recommendations on information to provide at multiple points in the pathway.

Axel Bex (AB) was an author on a paper included in the evidence review (RQ1 on

information needs) being discussed. It was agreed that the member would need to remain silent but could remain in the room whilst recommendations about information to be provided about biopsy were being made because this constituted one small section of the information needs recommendation drafting.

Finally, the minutes from committee 11 (day 1) were checked and agreed to be an accurate record.

2. RQ2b (for adults who have had treatment for localised or locally advanced renal cell carcinoma, what are the most clinically and cost-effective risk-stratified follow-up strategies based on method, duration, and frequency):

- **Reminder of clinical evidence and previous discussions**
- **Reminder of equality and health inequality issues**

The Chair introduced Agnesa Mehmeti (AM), Technical Analyst who presented a recap of the clinical evidence for follow-up for adults who have had treatment for localised or locally advanced renal cell carcinoma and the previously identified equality and health inequality issues.

BS thanked AM for her contribution.

3. Expert testimony for cost-effectiveness of biopsy

The Chair introduced Lindsay Claxton (LC), Health Economics Adviser who provided an overview of health economic metrics including ICERs and QALYs and a reminder of the cost-effectiveness results for biopsy in diagnosing T1 renal tumours.

The Chair thanked LC for her input before the expert witness joined the meeting.

The Chair introduced Professor Elena Pizzo (EP), Professorial Research Fellow and Health Economist at University College London who provided expert testimony on the cost-effectiveness of biopsy for adults who have had treatment for localised or locally advanced renal cell carcinoma.

The committee had the opportunity to ask questions.

BS thanked EP for their presentation, and she left the meeting.

4. Committee discussion and recommendation drafting

The Chair introduced Marie Harrisingh (MH), Topic Lead who led the group discussion of the evidence and drafting of initial wording for recommendations for biopsy which will be taken away for further edits.

The Chair thanked the group for their expertise and GS left the meeting at this point due to a conflict of interest.

5. Recommendation drafting for RQ1 (information needs)
<p>MH reminded the committee of the qualitative evidence and initial discussions from the last meeting and the group started to draft recommendations for what information, adults with suspected or confirmed RCC want before, during and after treatment.</p> <p>Axel Bex (AB) withdrew from participating in recommendation drafting regarding information around biopsy due to a conflict of interest but could draft recommendations on information to be provided at other stages of the treatment pathway.</p> <p>The Chair thanked the committee for their input.</p>
6. Review of full guideline:
<ul style="list-style-type: none">• Overall structure
<p>GS rejoined the meeting.</p> <p>MH presented the full guideline for committee input on the draft structure.</p> <p>The committee offered their opinion on appropriate sections and reordering recommendations. Changes will be made accordingly.</p> <p>The Chair thanked the committee for their input.</p>
7. Next steps and AOB
<p>BS summarised the main actions from the day and asked for items of any other business. As there was no further business to discuss, BS brought the meeting to a close.</p>

Date of next meeting: 03/06/2025

Location of next meeting: Virtual